FDA Accepts Palvella's QTORIN Rapamycin NDA, Grants Priority Review; PDUFA Set for Feb 28, 2027

summarizeSummary

The FDA accepted Palvella's NDA for QTORIN rapamycin in microcystic lymphatic malformations and granted Priority Review, with a PDUFA target action date of February 28, 2027. Approval would make it the first FDA-approved therapy for the disease, and the company is preparing a U.S. launch in the first half of 2027.

check_boxKey Events · Product Development and Regulatory · PVLA

• FDA Accepts NDA, Grants Priority Review

  The FDA accepted for filing Palvella's NDA for QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations and granted Priority Review.

• PDUFA Date Set for February 28, 2027

  The FDA assigned a Prescription Drug User Fee Act target action date of February 28, 2027, putting a firm decision date on the lead program.

• First-in-Disease Opportunity

  If approved, QTORIN rapamycin would be the first FDA-approved therapy for microcystic LMs, a condition affecting an estimated more than 30,000 diagnosed children and adults in the U.S. with no approved treatments.

• Launch Build-Out Underway

  Palvella is preparing for a potential standalone U.S. commercial launch in the first half of 2027, with rare disease commercial leadership, a field medical science liaison team, and a patient services organization already in place.

auto_awesomeAnalysis · PVLA · Life Sciences

This is the binary regulatory event the entire thesis rests on. FDA acceptance plus Priority Review compresses the review clock to a February 28, 2027 target action date, and approval would make QTORIN rapamycin the first FDA-approved therapy for microcystic lymphatic malformations — a disease with an estimated 30,000-plus diagnosed patients in the U.S. and no approved treatment. Palvella is already staffing for a standalone U.S. launch in the first half of 2027, so the company is now a regulatory-decision story rather than a clinical-development story. The remaining risk is concentrated: a complete response letter or a delay would hit the stock hard, while approval converts Palvella into a commercial-stage rare disease company. The $250.6 million in cash reported with Q2 2026 results funds the launch build-out without an immediate need to raise.